WO2024061608A1 - Method for inhibiting the growth of malassezia restricta - Google Patents
Method for inhibiting the growth of malassezia restricta Download PDFInfo
- Publication number
- WO2024061608A1 WO2024061608A1 PCT/EP2023/074228 EP2023074228W WO2024061608A1 WO 2024061608 A1 WO2024061608 A1 WO 2024061608A1 EP 2023074228 W EP2023074228 W EP 2023074228W WO 2024061608 A1 WO2024061608 A1 WO 2024061608A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycine
- composition
- growth
- microbes
- weight
- Prior art date
Links
- 241001291477 Malassezia restricta Species 0.000 title claims abstract description 50
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 218
- 239000000203 mixture Substances 0.000 claims abstract description 161
- 239000004471 Glycine Substances 0.000 claims abstract description 109
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 31
- 244000005700 microbiome Species 0.000 claims abstract description 30
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000009467 reduction Effects 0.000 claims abstract description 13
- 210000004761 scalp Anatomy 0.000 claims description 27
- 208000001840 Dandruff Diseases 0.000 claims description 15
- 210000004209 hair Anatomy 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 229920001296 polysiloxane Polymers 0.000 description 20
- 239000007788 liquid Substances 0.000 description 15
- 239000006210 lotion Substances 0.000 description 15
- -1 scrub Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 230000003750 conditioning effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 241000555676 Malassezia Species 0.000 description 6
- 241000555688 Malassezia furfur Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 229940008099 dimethicone Drugs 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000008406 cosmetic ingredient Substances 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000001974 tryptic soy broth Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical class CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- VZWGRQBCURJOMT-UHFFFAOYSA-N Dodecyl acetate Chemical compound CCCCCCCCCCCCOC(C)=O VZWGRQBCURJOMT-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 241001147736 Staphylococcus capitis Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229940056099 polyglyceryl-4 oleate Drugs 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 229940043810 zinc pyrithione Drugs 0.000 description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 1
- WTXXSZUATXIAJO-OWBHPGMISA-N (Z)-14-methylpentadec-2-enoic acid Chemical compound CC(CCCCCCCCCC\C=C/C(=O)O)C WTXXSZUATXIAJO-OWBHPGMISA-N 0.000 description 1
- LPMBTLLQQJBUOO-KTKRTIGZSA-N (z)-n,n-bis(2-hydroxyethyl)octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(CCO)CCO LPMBTLLQQJBUOO-KTKRTIGZSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- NZXZINXFUSKTPH-UHFFFAOYSA-N 4-[4-(4-butylcyclohexyl)cyclohexyl]-1,2-difluorobenzene Chemical compound C1CC(CCCC)CCC1C1CCC(C=2C=C(F)C(F)=CC=2)CC1 NZXZINXFUSKTPH-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- IBYCEACZVUOBIV-UHFFFAOYSA-N 4-methylpentyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCC(C)C IBYCEACZVUOBIV-UHFFFAOYSA-N 0.000 description 1
- AUGIYYGVQDZOLU-UHFFFAOYSA-N 4-methylpentyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCC(C)C AUGIYYGVQDZOLU-UHFFFAOYSA-N 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000928573 Cutibacterium Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001291474 Malassezia globosa Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- IHUMNXSBUOIDQI-UHFFFAOYSA-N Triethanolamine myristate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCC(O)=O IHUMNXSBUOIDQI-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 229940114077 acrylic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UHHXUPJJDHEMGX-UHFFFAOYSA-K azanium;manganese(3+);phosphonato phosphate Chemical compound [NH4+].[Mn+3].[O-]P([O-])(=O)OP([O-])([O-])=O UHHXUPJJDHEMGX-UHFFFAOYSA-K 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- PPOZILIWLOFYOG-UHFFFAOYSA-N bis(2-hexyldecyl) hexanedioate Chemical compound CCCCCCCCC(CCCCCC)COC(=O)CCCCC(=O)OCC(CCCCCC)CCCCCCCC PPOZILIWLOFYOG-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- QFSKIUZTIHBWFR-UHFFFAOYSA-N chromium;hydrate Chemical compound O.[Cr] QFSKIUZTIHBWFR-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- KBODESQIOVVMAI-UHFFFAOYSA-N decyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCC KBODESQIOVVMAI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940031766 diethanolamine cetyl phosphate Drugs 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- DFQOCHPHORLRID-UHFFFAOYSA-N dodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCC DFQOCHPHORLRID-UHFFFAOYSA-N 0.000 description 1
- ANXXYABAFAQBOT-UHFFFAOYSA-N dodecyl-methyl-bis(trimethylsilyloxy)silane Chemical compound CCCCCCCCCCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C ANXXYABAFAQBOT-UHFFFAOYSA-N 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 1
- RSRQBSGZMPVCOI-UHFFFAOYSA-N hexadecyl propanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CC RSRQBSGZMPVCOI-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000003077 lignite Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940102545 peg-20 sorbitan isostearate Drugs 0.000 description 1
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- VAKMIIPDYZXBEV-DPMBMXLASA-M potassium;(z,12r)-12-hydroxyoctadec-9-enoate Chemical compound [K+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O VAKMIIPDYZXBEV-DPMBMXLASA-M 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080279 sodium cocoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045905 sodium tallowate Drugs 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- SJXYCCRUTIHMCE-GOXDOWKOSA-K tripotassium;(z)-12-hydroxyoctadec-9-enoate;propane-1,2,3-triol Chemical compound [K+].[K+].[K+].OCC(O)CO.CCCCCCC(O)C\C=C/CCCCCCCC([O-])=O.CCCCCCC(O)C\C=C/CCCCCCCC([O-])=O.CCCCCCC(O)C\C=C/CCCCCCCC([O-])=O SJXYCCRUTIHMCE-GOXDOWKOSA-K 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Definitions
- the present invention relates to method for microbiome balancing on an external surface of a human body, preferably on human skin or scalp, more preferably on scalp.
- the invention relates to the use of glycine or a composition comprising a glycine for inhibiting the growth of harmful microbes which is Malassezia restricta.
- the invention also relates to the use of glycine or a composition comprising a glycine on microbiome balancing on an external surface of a human body.
- Microbes e.g. bacteria, fungi, viruses, protozoa and mites are often found to be present on surfaces such as fabrics, hard surfaces and skin.
- Microbiome of a surface refers to this entire population of microbes that are present on a surface. Some of the microbes present on the surface considered to be beneficial whereas some of the other microbes that co-habits with the good microbes are detrimental in nature.
- the scalp microbiome has recently become the focus of some attention for a potential causative role in dandruff progression.
- the major fungal/bacterial species present on the scalp namely Malassezia restricta, Malassezia globosa, Cutibacterium acnes, Staphylococcus epidermidis and Staphylococcus capitis.
- the lipophilic yeast Malasssezia restricta is known associated with dandruff condition.
- Antifungals, such as zinc pyrithione, piroctone olamine, and selenium sulfide, have been demonstrated to be effective anti-dandruff agents by reducing the growth of Malassezia on scalp.
- Staphylococcus and Cutibacterium are the most abundant bacteria genera across both healthy and dandruff scalps. However, at species level, Staphylococcus capitis is reported to be positively associated with dandruff conditions, while Staphylococcus epidermidis and Cutibacterium acnes, are considered as commensal bacteria, which are is positively associated with non-dandruff scalp conditions in terms of relative or absolute abundance.
- Antimicrobial compositions are commonly used by individuals to eliminate or reduce the number of harmful microbes.
- broad-spectrum antimicrobial composition such as zinc pyrithione, may also kills or inhibit the microbes which are beneficial.
- glycine or a composition comprising glycine at certain level can inhibit the growth of Malassezia restricta when applied on an external surface of a human body, while having no inhibition effect on the commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes.
- the present invention is directed to use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the present invention is directed to use of of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes while protecting the surface against harmful microbes which is Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the present invention is directed to glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the present inventio is directed to glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- any feature of one aspect of the present invention may be utilized in any other aspect of the invention.
- the word “comprising” is intended to mean “including” but not necessarily “consisting of or “composed of.” In other words, the listed steps or options need not be exhaustive. It is noted that the examples given in the description below are intended to clarify the invention and are not intended to limit the invention to those examples per se. Similarly, all percentages are weight/weight percentages unless otherwise indicated. Except in the operating and comparative examples, or where otherwise explicitly indicated, all numbers in this description and claims indicating amounts of material or conditions of reaction, physical properties of materials and/or use are to be understood as modified by the word "about”.
- Numerical ranges expressed in the format “from x to y” are understood to include x and y. When for a specific feature multiple preferred ranges are described in the format “from x to y", it is understood that all ranges combining the different endpoints are also contemplated.
- the indefinite article “a” or “an” and its corresponding definite article “the” means at least one, or one or more, unless specified otherwise.
- the various features of the present invention referred to in individual sections above apply, as appropriate, to other sections mutatis mutandis. Consequently, features specified in one section may be combined with features specified in other sections as appropriate. Any section headings are added for convenience only and are not intended to limit the disclosure in any way.
- “Hair care composition”, as used herein, is meant to include a composition for topical application to hair and/or scalp of mammals, especially humans. Such a composition may be generally classified as leave-on or rinse off, and includes any product applied to a human body for also improving appearance, cleansing, odor control or general aesthetics.
- the composition of the present invention can be in the form of a liquid, lotion, cream, foam, scrub, gel, or bar. Non-limiting examples of such compositions include leave-on hair lotions, creams, and rinse-off shampoos, conditioners, shower gels, or toilet bar.
- a microbe can be described as a tiny living organism, such as bacterium, fungus, virus protozoan, or mite.
- a microbiome on a surface refers collectively to all the microbes on the surface. In other words, a microbiome is a community of microbes.
- microbiome balancing means selectively eliminating/killing/reducing the microbes considered to be harmful existing on a surface whereas keeping the microbes considered to be beneficial substantially at the same level or even increasing the number of microbes which are considered to be beneficial.
- Malassezia restricta (M. restricta), which a lipophilic yeast and one of the most abundant Malassezia species of the human skin microbiota. M. restricts is considered an opportunistic pathogen associated with skin disorders, such as seborrheic dermatitis and dandruff.
- At least one of the microbes considered to be beneficial is Staphylococcus epidermidis (S. epidermidis).
- S. epidermidis is reported to be a beneficial bacterium that participates in the maintenance of skin health. It is a kind of normal microbe which is likely to be involved in competitive exclusion of pathogens. It is thus an indication of microbiome status of the surface. The increase and maintenance of S. epidermidis is an important route to maintain the composition of healthy microbiome.
- At least one of the microbes considered to be beneficial is Cutibacterium acnes (C. ances). It is one or the main bacterial species that have been identified on the healthy scalp.
- the present invention relates to the use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body.
- the surface is preferably human skin, for example, a surface like the hands, face, body or scalp. More preferably, the surface is scalp.
- Microbiome balancing is obtained by selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from S. epidermidis and C. acnes.
- the present invention relates to use of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body.
- the surface is preferably human skin, for example, a surface like the hands, face, body or scalp. More preferably, the surface is scalp.
- glycine or the composition in accordance with the present invention has less impact on the growth of microbes of other Malassezia genus, such as Malassezia furfur.
- the use of glycine or the composition in accordance with the present invention has no inhibition effect on the growth of Malassezia furfur.
- Glycine is an amino acid which is essential in the production of collagen, a protein that gives structure to bones, skin, muscles, and connective tissues. It is the simplest stable amino acid, with the chemical formula NH2-CH2-COOH.
- Amino acids are usually considered as nutrient source for both microorganisms and human. It is surprisingly to be found that glycine or the composition comprising glycine at certain level can inhibit the growth of Malassezia restricta when applied on a surface. However such use has no inhibition effect on the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes. Therefore, such use can provide microbiome balancing, selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from S. epidermidis and C. acnes.
- composition of the present invention comprises at least 0.04% of glycine, preferably at least 0.1% of glycine, more preferably at least 0.15% of glycine by weight of the composition.
- the composition comprises from 0.04 to 10% of glycine, preferably from 0.1% to 5% of glycine, more preferably from 0.15 to 2%, furthermore preferably from 0.2 to 2% by weight of the total composition and including all ranges subsumed therein.
- the minium preferred concentration of the glycine can be higher. It is generally preferred that the concentration of the glycine in the composition in the use according to the present invention is equal or higher than the optimal concentrations in the working composition, because in many typical applications, the composition is either used pure or is diluted to form the working composition.
- the lather produced typically is a 50 wt% dilution of the original composition. Similary, in hair wash , body wash situations, liquids soap or bars are typically diluted until about 8 wt% to 10wt% in water, corresponding to an approximately tenfould dilution of the product.
- the concentration of the glycine in the composition is preferably such that, when the composition is diluted or dissolved with a suitable medium before or during use, the concentration in the diluted or dissolved mixture is still sufficient to provides microbiome balancing benefits on an external surface of a human body.
- the composition is preferably a personal care composition.
- a personal care composition is a composition for the treatment, cleaning, caring or conditioning of the person.
- the foregoing includes, but not limited to, chemicals, compositions, products, or combinations thereof relating to or having use or application in the treatment, cleansing or conditioning of the person (including in particular the skin, hair, scalp and oral cavity), and the manufacture of all the foregoing.
- Examples of a personal care composition include but not limited to leave-on skin lotions and creams, shampoos, conditioners, shower gels, soap bars, antiperspirants, deodorants, shave creams, depilatories, lipsticks, foundations, mascara, sunless tanners or sunscreen lotions.
- the composition is leave-on personal care composition.
- Preferred personal care compositions for use in the invention include rinse-off or leave- on hair or scalp care compositions such as shampoos, conditioners, creams, lotions, gels, serums, mousses or oils.
- Leave-on hair or scalp care compositions are preferred, such as lotions, serums, oils, which are intended for topical application to the hair or scalp.
- compositions for use in the invention will generally include a cosmetically acceptable carrier.
- Cosmetically acceptable means that the carrier is suitable for topical application to the skin, has good aesthetic properties, is compatible with any other ingredients, and will not cause any safety or toxicity concerns.
- the carrier may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase or a mixture thereof, and may be in the form of an emulsion.
- Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams and heavy creams.
- compositions for use in the invention may also be formulated in a single-phase carrier such as a hydrophobic or hydrophilic liquid.
- Suitable hydrophobic liquid carriers include liquid polyorganosiloxanes, mineral oils, hydrogenated polyisobutene, polydecene, paraffins and isoparaffins of at least 10 carbon atoms, aliphatic or aromatic ester oils (such as isopropyl myristate, lauryl myristate, isopropyl palmitate, diisopropyl sebacate, diisopropyl adipate and C12 to C15 alkyl benzoates), polyglycol ethers (such as polyglycol butanol ethers) and mixtures thereof.
- Suitable hydrophilic liquid carriers include water, monohydric or polyhydric aliphatic alcohols having 2 to 8, preferably 2 or 3 carbon atoms (such as ethanol and isopropanol, oligoglycol ethers having 2 to 5 repeat units (such as dipropylene glycol) and mixtures thereof.
- a particularly preferred carrier is water.
- Liquid form compositions for use in the invention may be thickened, for example using one or more water soluble or colloidally water soluble polymeric thickening agents.
- composition for use in the invention comprises a thickening agent.
- Suitable water soluble or colloidally water soluble polymeric thickening agents include hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquaternium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, crosslinked polyacrylate polymers and polyacrylamide polymers.
- the composition for use in the invention may additionally comprise a conditioning agent to provide conditioning benefit.
- the composition comprises discrete dispersed droplets of a water-insoluble conditioning agent, which has a mean droplet diameter (D3,2) of less than 15 microns, preferably less than 10 microns, more preferably less than 5 microns, most preferably less than 3 microns.
- the mean droplet diameter (D3,2) of a water-insoluble conditioning agent may be measured by means of a laser light scattering technique, for example using a 2600D Particle Sizer from Malvern Instruments.
- the water-insoluble conditioning agent may include non-silicone conditioning agent comprising non-silicone oily or fatty materials such as hydrocarbon oils, fatty esters and mixtures thereof.
- the water-insoluble conditioning agent is emulsified silicone oil.
- Suitable silicones include polydiorganosiloxanes, in particular polydimethylsiloxanes which have the CTFA designation dimethicone.
- polydimethyl siloxanes having hydroxyl end groups which have the CTFA designation dimethiconol.
- silicone gums having a slight degree of cross-linking, as are described for example in WO 96/31188.
- the silicone oil comprises dimethicone, dimethiconol or a mixture thereof.
- Suitable emulsified silicones included in the compositions for use in this invention are available as pre-formed silicone emulsions from suppliers of silicones such as Dow Corning and GE silicones. The use of such pre-formed silicone emulsion is preferred for ease of processing and control of silicone particle size.
- Such pre-formed silicone emulsions will typically additionally comprise a suitable emulsifier, and may be prepared by a chemical emulsification process such as emulsion polymerisation, or by mechanical emulsification using a high shear mixer.
- suitable pre-formed silicone emulsions include DC1785, DC1788, DC7128, all available from Dow Corning. These are emulsions of dimethiconol/dimethicone.
- silicones which may be used are functionalized silicones such as amino functional silicones, meaning a silicone containing at least one primary, secondary or tertiary amine group, or a quaternary ammonium group.
- suitable amino functional silicones include polysiloxanes having the CTFA designation “amodimethicone.”
- the water-insoluble conditioning agent is generally present in the composition for use in this invention in an amount from 0.05 to 15%, preferably from 0.1 to 10%, more preferably from 0.5 to 8%, most preferably from 1 to 5%, based on total weight of the composition.
- the pH of the composition for use according to the present invention is preferably equal to or higher than 4.0, more preferably in the range of 5.0 to 10.0.
- Oils and lotions for use in the invention typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room temperature (25°C).
- Lotions are typically aqueous emulsions having an aqueous phase in addition to the oil phase.
- Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of polyols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl ole
- the aqueous phase of lotions for use in the invention may also include one or more organic liquids that are miscible with water at room temperature (25°C).
- exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C2-C6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C3- C16 glycol ethers (such as mono-, di-, or tripropylene glycol (C1-C4) alkyl ethers and mono-, di-, or triethylene glycol (C1-C4) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
- C2-C6 alkanols such as ethanol and isopropan
- Lotions for use in the invention may also include surface active ingredients, such as emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition.
- Emulsifiers that may be used to form O/W or W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate
- Compositions for use in the invention may include additional actives for improving the physical and/or aesthetic characteristics of the scalp and/or the hair.
- additional actives for improving the physical and/or aesthetic characteristics of the scalp and/or the hair.
- examples include amino acids, vitamins, minerals and/or antioxidants, emollients, humectants, sunscreens, anti-irritants, exfoliating agents, botanical extracts (such as pomegranate, white birch, green tea, chamomile and licorice extracts) and mixtures thereof.
- Compositions for use in the invention may include additional functional ingredients for improving the physical and/or aesthetic characteristics of the composition per se.
- additional functional ingredients include inorganic pigments (such as titanium oxide, zirconium oxide, cerium oxide, zinc oxide, iron oxide, chromium oxide, manganese violet, ultramarine blue, chromium hydrate and ferric blue); organic pigments (such as carbon black and the organic lakes of barium, strontium, calcium or aluminium); pearlescent agents (such as mica coated with titanium oxide and/or iron oxide); dyes, preservatives (such as disodium EDTA, benzyl alcohol, methylparaben, phenoxyethanol, propylparaben, ethylparaben, butylparaben and isobutylparaben); pH adjusters and fragrances (such as essential oils, flower oils, natural extracts from resins, gums, balsams, beans, mosses and other plants, as well as synthetic aromatic materials).
- inorganic pigments such as titanium oxide,
- Preservatives may also be incorporated into the composition for use in this invention to protect against the growth of potentially harmful microorganisms.
- Suitable traditional preservatives include alkyl esters of parahydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds.
- preservatives include, for examples, phenoxyethanol, sodium salicylate, methyl paraben, butyl paraben, propyl paraben, diazolidinyl urea, sodium dehydroacetate, benzyl alcohol, sodium benzoate, iodopropynyl butylcarbamate, caprylyl glycol, disodium EDTA or mixtures thereof.
- the preservative is sodium benzoate, phenoxyethanol, sodium salicylate or a mixture thereof.
- Preservatives are preferably employed in amounts ranging from 0.01 to 2% by weight of the composition.
- the composition for use in the invention comprises a cosmetic ingredient.
- the cosmetic ingredient is selected from the group consisting of a silicone, an antibacterial agent other than antidandruff agents, a foam booster, a perfume, encapsulates (for example encapsulated fragrance) a dye, a colouring agent, a pigment, a preservative, a thickener, a protein, a phosphate ester, a buffering agent, a pH adjusting agent, a pearlescer (for example; mica, titanium dioxide, titanium dioxide coated mica, ethylene glycol distearate (INCI glycol distearate)) and/or opacifier, a viscosity modifier, an emollient, a sunscreen, an emulsifier, a sensate active (for example menthol and menthol derivatives), vitamins, mineral oils, essential oils, lipids, natural actives, glycerin, natural hair nutrients such as botanical extracts, fruit extracts, sugar derivatives and amino acids, micro
- the composition for use in the present invention includes from 0.01 to 20 wt% of the at least one cosmetic ingredient, more preferably from 0.05 to 10 wt%, still more preferably from 0.075 to 7.5 wt% and most preferably, from 0.1 to 5 wt% of the at least one cosmetic ingredient, by weight of the total composition.
- the present invention provides for use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
- the use is preferably non-therapeutic in nature, more preferably cosmetic in nature.
- the present invention provides for use of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- Such microbiome balancing can be used for the treatment of dandruff.
- the use is preferably non-therapeutic in nature, more preferably cosmetic in nature.
- the present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
- the method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
- the present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- microbiome balancing can be used for the treatment of dandruff.
- the method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
- the present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes while protecting the surface against harmful microbes which is Malassezia restricta, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
- the present invention provides for glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
- the present invention provides for glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- Such microbiome balancing can be used for the treatment of dandruff.
- the present invention provides for glycine or a composition comprising glycine for use as a medicament. It provides for glycine or a composition comprising glycine for use as a medication for inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- glycine or a composition comprising glycine for use as a medication for microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
- the composition is suitably applied to the hair or scalp and massaged into the surface of the scalp.
- an amount corresponding to about 1 to 15 ml of the composition per application is applied uniformly over the area of treatment daily or at least once a week over a time interval of at least 7 (seven) days, preferably at least 28 days, more preferably at least 30 (thirty) days.
- the invention will be further illustrated by the following, non-limiting Examples.
- M. restricta (CBS 7877) was revitalized on modified Leeming and Notman agar (mLNA) plates from -80 °C freezer by incubation at 32 °C for 5 days.
- the microbe was further cultured in 20ml of liquid growth medium modified Leeming and Notman broth (mLNB) at 32 °C for 48 hrs with shaking. Then, 1ml of the first broth culture was transferred into 9 ml of fresh mLNB and incubated at 32 °C for 48 hrs with shaking and ready to use.
- mLNB liquid growth medium modified Leeming and Notman broth
- CBS 1878 Malassezia. furfur (CBS 1878) was revitalized on Pityrosporum Broth (PB) agar by incubation at 32 °C for 2 days. The microbe was further cultured in 20) ml of liquid growth medium PB broth at 32 °C for 48 hrs with shaking. Then, 1ml of the first broth culture is transferred into 9ml of fresh PB and incubated at 32 °C for 48 hrs with shaking and ready to use.
- PB Pityrosporum Broth
- S. epidermidis (ATCC_12228) was revitalized on Tryptic soy agar (TSA) by incubation at 37 °C overnight.
- TSA Tryptic soy agar
- the microbe was further cultured in 20 ml of liquid growth medium Tryptic soy broth (TSB) at 37 °C overnight and ready to use.
- TSA Tryptic soy agar
- C. acnes (ATCC_6919) were revitalized on TSA plates by incubation at 37 °C for 5 days anaerobically.
- the microbe was further cultured in 20 ml of liquid growth medium TSB at 37 °C for 4 days anaerobically and ready to use.
- OD optical density
- samples 1 to 5 comprising glycine at a level consistent with the present invention were able to selectively inhibit the growth of harmful microbes (/W. restricta) while having no inhibition effect on the growth of beneficial microbes (S.epidermidis and C. acnes). Furthermore, the result in table above indicates that the using of composition comprising glycine at a level consistent with the present invention has less impact on the number of other Malassezia genus, such as Malassezia furfur (M. furfur).
- M. restricta Malassezia restricta
- M. restricta growth was monitored with or without adding 0.5% of different amino acids by culturing M. restricta in mLNB liquid medium for 3 days.
- the pH of the solutions was all adjusted to the same level of pH 5.5. The same protocol was used to observe the growth of the microbes.
- sample 6 comprising glycine at a level consistent with the present invention were able to inhibit the growth of harmful microbes ⁇ M. restricta), while the samples comprising other amino acids cannot.
- compositions comprising glycine at a level consistent with the present invention were able to inhibit the growth of harmful microbes (M. restricta).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition. It also relates to use of glycine or a composition comprising glycine in microbiome balancing on a surface, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
Description
METHOD FOR INHIBITING THE GROWTH OF MALASSEZIA RESTRICTA
Field of the Invention
The present invention relates to method for microbiome balancing on an external surface of a human body, preferably on human skin or scalp, more preferably on scalp. In particular, the invention relates to the use of glycine or a composition comprising a glycine for inhibiting the growth of harmful microbes which is Malassezia restricta. The invention also relates to the use of glycine or a composition comprising a glycine on microbiome balancing on an external surface of a human body.
Background of the Invention
Microbes e.g. bacteria, fungi, viruses, protozoa and mites are often found to be present on surfaces such as fabrics, hard surfaces and skin. Microbiome of a surface refers to this entire population of microbes that are present on a surface. Some of the microbes present on the surface considered to be beneficial whereas some of the other microbes that co-habits with the good microbes are detrimental in nature.
The scalp microbiome has recently become the focus of some attention for a potential causative role in dandruff progression. The major fungal/bacterial species present on the scalp, namely Malassezia restricta, Malassezia globosa, Cutibacterium acnes, Staphylococcus epidermidis and Staphylococcus capitis. The lipophilic yeast Malasssezia restricta is known associated with dandruff condition. Antifungals, such as zinc pyrithione, piroctone olamine, and selenium sulfide, have been demonstrated to be effective anti-dandruff agents by reducing the growth of Malassezia on scalp. Staphylococcus and Cutibacterium are the most abundant bacteria genera across both healthy and dandruff scalps. However, at species level, Staphylococcus capitis is reported to be positively associated with dandruff conditions, while Staphylococcus epidermidis and Cutibacterium acnes, are considered as commensal bacteria, which are is positively associated with non-dandruff scalp conditions in terms of relative or absolute abundance.
Antimicrobial compositions are commonly used by individuals to eliminate or reduce the number of harmful microbes. However, the application of broad-spectrum
antimicrobial composition, such as zinc pyrithione, may also kills or inhibit the microbes which are beneficial.
There is a continuing need for treatments which are capable of providing microbiome balancing by selectively reducing the number of harmful microbes while having less effect on or selectively increasing the number of beneficial microbes.
Summary of the Invention
The present inventors have surprisingly found that glycine or a composition comprising glycine at certain level can inhibit the growth of Malassezia restricta when applied on an external surface of a human body, while having no inhibition effect on the commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes.
In a first aspect, the present invention is directed to use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
In a second aspect, the present invention is directed to use of of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
In a third aspect, the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
In a fourth aspect, the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful
microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
In a fifth aspect, the present invention is directed to a method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes while protecting the surface against harmful microbes which is Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
In a sixth aspect, the present invention is directed to glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
In a seventh aspect, the present inventio is directed to glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.
Detailed Description
For the avoidance of doubt, any feature of one aspect of the present invention may be utilized in any other aspect of the invention. The word "comprising" is intended to mean "including" but not necessarily "consisting of or "composed of." In other words, the listed steps or options need not be exhaustive. It is noted that the examples given in the description below are intended to clarify the invention and are not intended to limit the invention to those examples per se. Similarly, all percentages are weight/weight percentages unless otherwise indicated. Except in the operating and comparative
examples, or where otherwise explicitly indicated, all numbers in this description and claims indicating amounts of material or conditions of reaction, physical properties of materials and/or use are to be understood as modified by the word "about". Numerical ranges expressed in the format "from x to y" are understood to include x and y. When for a specific feature multiple preferred ranges are described in the format "from x to y", it is understood that all ranges combining the different endpoints are also contemplated. As used herein, the indefinite article “a” or “an” and its corresponding definite article “the” means at least one, or one or more, unless specified otherwise. The various features of the present invention referred to in individual sections above apply, as appropriate, to other sections mutatis mutandis. Consequently, features specified in one section may be combined with features specified in other sections as appropriate. Any section headings are added for convenience only and are not intended to limit the disclosure in any way.
“Hair care composition”, as used herein, is meant to include a composition for topical application to hair and/or scalp of mammals, especially humans. Such a composition may be generally classified as leave-on or rinse off, and includes any product applied to a human body for also improving appearance, cleansing, odor control or general aesthetics. The composition of the present invention can be in the form of a liquid, lotion, cream, foam, scrub, gel, or bar. Non-limiting examples of such compositions include leave-on hair lotions, creams, and rinse-off shampoos, conditioners, shower gels, or toilet bar.
Microbes
A microbe can be described as a tiny living organism, such as bacterium, fungus, virus protozoan, or mite. A microbiome on a surface refers collectively to all the microbes on the surface. In other words, a microbiome is a community of microbes.
The term “microbiome balancing” as used herein, means selectively eliminating/killing/reducing the microbes considered to be harmful existing on a surface whereas keeping the microbes considered to be beneficial substantially at the same level or even increasing the number of microbes which are considered to be beneficial.
The microbe considered to be harmful is Malassezia restricta (M. restricta), which a lipophilic yeast and one of the most abundant Malassezia species of the human skin
microbiota. M. restricts is considered an opportunistic pathogen associated with skin disorders, such as seborrheic dermatitis and dandruff.
At least one of the microbes considered to be beneficial is Staphylococcus epidermidis (S. epidermidis). S. epidermidis is reported to be a beneficial bacterium that participates in the maintenance of skin health. It is a kind of normal microbe which is likely to be involved in competitive exclusion of pathogens. It is thus an indication of microbiome status of the surface. The increase and maintenance of S. epidermidis is an important route to maintain the composition of healthy microbiome.
At least one of the microbes considered to be beneficial is Cutibacterium acnes (C. ances). It is one or the main bacterial species that have been identified on the healthy scalp.
The present invention relates to the use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body. However, such use has no inhibition effect on the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes. The surface is preferably human skin, for example, a surface like the hands, face, body or scalp. More preferably, the surface is scalp.
Microbiome balancing is obtained by selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from S. epidermidis and C. acnes.
The present invention relates to use of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body. The surface is preferably human skin, for example, a surface like the hands, face, body or scalp. More preferably, the surface is scalp.
It is also surprisingly to find that the use of glycine or the composition in accordance with the present invention has less impact on the growth of microbes of other Malassezia genus, such as Malassezia furfur. The use of glycine or the composition in accordance with the present invention has no inhibition effect on the growth of Malassezia furfur.
Glycine
Glycine is an amino acid which is essential in the production of collagen, a protein that gives structure to bones, skin, muscles, and connective tissues. It is the simplest stable amino acid, with the chemical formula NH2-CH2-COOH.
Amino acids are usually considered as nutrient source for both microorganisms and human. It is surprisingly to be found that glycine or the composition comprising glycine at certain level can inhibit the growth of Malassezia restricta when applied on a surface. However such use has no inhibition effect on the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes. Therefore, such use can provide microbiome balancing, selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from S. epidermidis and C. acnes.
The composition of the present invention comprises at least 0.04% of glycine, preferably at least 0.1% of glycine, more preferably at least 0.15% of glycine by weight of the composition.
It is preferred that the composition comprises from 0.04 to 10% of glycine, preferably from 0.1% to 5% of glycine, more preferably from 0.15 to 2%, furthermore preferably from 0.2 to 2% by weight of the total composition and including all ranges subsumed therein.
In compositions intended to be diluted before application, the minium preferred concentration of the glycine can be higher. It is generally preferred that the concentration of the glycine in the composition in the use according to the present invention is equal or higher than the optimal concentrations in the working composition, because in many typical applications, the composition is either used pure or is diluted to form the working composition. For example, when washing hands with water and a composition of the present invention, the lather produced, typically is a 50 wt% dilution of the original composition. Similary, in hair wash , body wash situations, liquids soap or bars are typically diluted until about 8 wt% to 10wt% in water, corresponding to an approximately tenfould dilution of the product. Therefore, the concentration of the glycine in the composition is preferably such that, when the composition is diluted or dissolved with a suitable medium before or during use, the concentration in the diluted
or dissolved mixture is still sufficient to provides microbiome balancing benefits on an external surface of a human body.
The composition is preferably a personal care composition. A personal care composition is a composition for the treatment, cleaning, caring or conditioning of the person. The foregoing includes, but not limited to, chemicals, compositions, products, or combinations thereof relating to or having use or application in the treatment, cleansing or conditioning of the person (including in particular the skin, hair, scalp and oral cavity), and the manufacture of all the foregoing. Examples of a personal care composition include but not limited to leave-on skin lotions and creams, shampoos, conditioners, shower gels, soap bars, antiperspirants, deodorants, shave creams, depilatories, lipsticks, foundations, mascara, sunless tanners or sunscreen lotions. Preferably, the composition is leave-on personal care composition.
Preferred personal care compositions for use in the invention include rinse-off or leave- on hair or scalp care compositions such as shampoos, conditioners, creams, lotions, gels, serums, mousses or oils. Leave-on hair or scalp care compositions are preferred, such as lotions, serums, oils, which are intended for topical application to the hair or scalp.
Compositions for use in the invention will generally include a cosmetically acceptable carrier. The term “cosmetically acceptable” means that the carrier is suitable for topical application to the skin, has good aesthetic properties, is compatible with any other ingredients, and will not cause any safety or toxicity concerns.
The carrier may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase or a mixture thereof, and may be in the form of an emulsion. Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams and heavy creams.
Compositions for use in the invention may also be formulated in a single-phase carrier such as a hydrophobic or hydrophilic liquid. Suitable hydrophobic liquid carriers include liquid polyorganosiloxanes, mineral oils, hydrogenated polyisobutene, polydecene, paraffins and isoparaffins of at least 10 carbon atoms, aliphatic or
aromatic ester oils (such as isopropyl myristate, lauryl myristate, isopropyl palmitate, diisopropyl sebacate, diisopropyl adipate and C12 to C15 alkyl benzoates), polyglycol ethers (such as polyglycol butanol ethers) and mixtures thereof. Suitable hydrophilic liquid carriers include water, monohydric or polyhydric aliphatic alcohols having 2 to 8, preferably 2 or 3 carbon atoms (such as ethanol and isopropanol, oligoglycol ethers having 2 to 5 repeat units (such as dipropylene glycol) and mixtures thereof. A particularly preferred carrier is water.
Liquid form compositions for use in the invention may be thickened, for example using one or more water soluble or colloidally water soluble polymeric thickening agents.
It is preferred that the composition for use in the invention comprises a thickening agent.
Suitable water soluble or colloidally water soluble polymeric thickening agents include hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquaternium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, crosslinked polyacrylate polymers and polyacrylamide polymers.
The composition for use in the invention may additionally comprise a conditioning agent to provide conditioning benefit. Preferably, the composition comprises discrete dispersed droplets of a water-insoluble conditioning agent, which has a mean droplet diameter (D3,2) of less than 15 microns, preferably less than 10 microns, more preferably less than 5 microns, most preferably less than 3 microns. The mean droplet diameter (D3,2) of a water-insoluble conditioning agent may be measured by means of a laser light scattering technique, for example using a 2600D Particle Sizer from Malvern Instruments.
The water-insoluble conditioning agent may include non-silicone conditioning agent comprising non-silicone oily or fatty materials such as hydrocarbon oils, fatty esters and mixtures thereof. Preferably, the water-insoluble conditioning agent is emulsified silicone oil.
Suitable silicones include polydiorganosiloxanes, in particular polydimethylsiloxanes which have the CTFA designation dimethicone. Also suitable for use in compositions of this invention (particularly shampoos and conditioners) are polydimethyl siloxanes having hydroxyl end groups, which have the CTFA designation dimethiconol. Also suitable for use in compositions of this invention are silicone gums having a slight degree of cross-linking, as are described for example in WO 96/31188. Preferably, the silicone oil comprises dimethicone, dimethiconol or a mixture thereof.
Suitable emulsified silicones included in the compositions for use in this invention are available as pre-formed silicone emulsions from suppliers of silicones such as Dow Corning and GE silicones. The use of such pre-formed silicone emulsion is preferred for ease of processing and control of silicone particle size. Such pre-formed silicone emulsions will typically additionally comprise a suitable emulsifier, and may be prepared by a chemical emulsification process such as emulsion polymerisation, or by mechanical emulsification using a high shear mixer. Examples of suitable pre-formed silicone emulsions include DC1785, DC1788, DC7128, all available from Dow Corning. These are emulsions of dimethiconol/dimethicone.
Another class of silicones which may be used are functionalized silicones such as amino functional silicones, meaning a silicone containing at least one primary, secondary or tertiary amine group, or a quaternary ammonium group. Examples of suitable amino functional silicones include polysiloxanes having the CTFA designation “amodimethicone.”
The water-insoluble conditioning agent is generally present in the composition for use in this invention in an amount from 0.05 to 15%, preferably from 0.1 to 10%, more preferably from 0.5 to 8%, most preferably from 1 to 5%, based on total weight of the composition.
The pH of the composition for use according to the present invention is preferably equal to or higher than 4.0, more preferably in the range of 5.0 to 10.0.
Oils and lotions for use in the invention typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room
temperature (25°C). Lotions are typically aqueous emulsions having an aqueous phase in addition to the oil phase.
Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of polyols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl oleate, oleyl myristate, lauryl acetate, cetyl propionate, isononyl isononanoate, propylene glycol dicaprate, diisopropyl adipate, dibutyl adipate, and oleyl adipate); ethers (such as dicapryl ether); fatty alcohols (such as cetyl alcohol, stearyl alcohol and behenyl alcohol); isoparaffins (such as isooctane, isododecane and isohexadecane); silicone oils (such as cyclomethicone, dimethicone and dimethiconol); hydrocarbon oils (such as mineral oil, petrolatum and polyisobutene); fatty acids containing from 8 to 30 carbon atoms, (such as stearic acid, lauric acid, palmitic acid and oleic acid); vegetable fats (such as cocoa butter, coconut oil, palm oil and shea butter); petroleum-based, natural and synthetic waxes (such as lanolin wax, beeswax, carnauba wax, candelilla wax, paraffin wax, lignite wax, microcrystalline waxes, ceresin, ozokerite, and polyethylene waxes); hydrogenated oils which are solid at 25° C (such as hydrogenated castor oil, hydrogenated jojoba oil, hydrogenated palm oil, hydrogenated tallow and hydrogenated coconut oil) ;and fatty esters that are solid at 25°C (such as C20-40 alkyl stearate).
The aqueous phase of lotions for use in the invention may also include one or more organic liquids that are miscible with water at room temperature (25°C). Exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C2-C6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C3- C16 glycol ethers (such as mono-, di-, or tripropylene glycol (C1-C4) alkyl ethers and mono-, di-, or triethylene glycol (C1-C4) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
Lotions for use in the invention may also include surface active ingredients, such as emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition. Emulsifiers that may be used to form O/W or W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3- diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, cetyl phosphate, diethanolamine cetyl phosphate, potassium cetyl phosphate, sodium glyceryl oleate phosphate, dimethicone copolyol, cetyl dimethicone copolyol, octyldimethicone ethoxyglucoside copolyol, dimethicone copolyol crosspolymer and laurylmethicone copolyol.
Combinations of any of the above described materials or product forms may also be used.
Compositions for use in the invention (as described above) may include additional actives for improving the physical and/or aesthetic characteristics of the scalp and/or the hair. Examples include amino acids, vitamins, minerals and/or antioxidants, emollients, humectants, sunscreens, anti-irritants, exfoliating agents, botanical extracts (such as pomegranate, white birch, green tea, chamomile and licorice extracts) and mixtures thereof.
Compositions for use in the invention (as described above) may include additional functional ingredients for improving the physical and/or aesthetic characteristics of the composition per se. Examples include inorganic pigments (such as titanium oxide, zirconium oxide, cerium oxide, zinc oxide, iron oxide, chromium oxide, manganese violet, ultramarine blue, chromium hydrate and ferric blue); organic pigments (such as carbon black and the organic lakes of barium, strontium, calcium or aluminium); pearlescent agents (such as mica coated with titanium oxide and/or iron oxide); dyes, preservatives (such as disodium EDTA, benzyl alcohol, methylparaben, phenoxyethanol, propylparaben, ethylparaben, butylparaben and isobutylparaben); pH adjusters and fragrances (such as essential oils, flower oils, natural extracts from
resins, gums, balsams, beans, mosses and other plants, as well as synthetic aromatic materials).
Mixtures of any of the above described materials may also be used.
Preservatives may also be incorporated into the composition for use in this invention to protect against the growth of potentially harmful microorganisms. Suitable traditional preservatives include alkyl esters of parahydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Illustrative yet non-limiting examples of the types of preservatives that may be used in this invention include, for examples, phenoxyethanol, sodium salicylate, methyl paraben, butyl paraben, propyl paraben, diazolidinyl urea, sodium dehydroacetate, benzyl alcohol, sodium benzoate, iodopropynyl butylcarbamate, caprylyl glycol, disodium EDTA or mixtures thereof. In an especially preferred embodiment, the preservative is sodium benzoate, phenoxyethanol, sodium salicylate or a mixture thereof. Preservatives are preferably employed in amounts ranging from 0.01 to 2% by weight of the composition.
It is further preferred that the composition for use in the invention comprises a cosmetic ingredient. Preferably the cosmetic ingredient is selected from the group consisting of a silicone, an antibacterial agent other than antidandruff agents, a foam booster, a perfume, encapsulates (for example encapsulated fragrance) a dye, a colouring agent, a pigment, a preservative, a thickener, a protein, a phosphate ester, a buffering agent, a pH adjusting agent, a pearlescer (for example; mica, titanium dioxide, titanium dioxide coated mica, ethylene glycol distearate (INCI glycol distearate)) and/or opacifier, a viscosity modifier, an emollient, a sunscreen, an emulsifier, a sensate active (for example menthol and menthol derivatives), vitamins, mineral oils, essential oils, lipids, natural actives, glycerin, natural hair nutrients such as botanical extracts, fruit extracts, sugar derivatives and amino acids, microcrystalline cellulose and mixtures thereof.
Preferably, the composition for use in the present invention includes from 0.01 to 20 wt% of the at least one cosmetic ingredient, more preferably from 0.05 to 10 wt%, still more preferably from 0.075 to 7.5 wt% and most preferably, from 0.1 to 5 wt% of the at least one cosmetic ingredient, by weight of the total composition.
Method
The present invention provides for use of glycine or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff. The use is preferably non-therapeutic in nature, more preferably cosmetic in nature.
The present invention provides for use of glycine or a composition comprising glycine in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such microbiome balancing can be used for the treatment of dandruff. The use is preferably non-therapeutic in nature, more preferably cosmetic in nature.
The present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff. The method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
The present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
Such microbiome balancing can be used for the treatment of dandruff. The method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
The present invention provides for a method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium
acnes while protecting the surface against harmful microbes which is Malassezia restricta, wherein the composition comprises at least 0.04% of glycine by weight of the composition. The method is preferably non-therapeutic in nature, more preferably cosmetic in nature.
The present invention provides for glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such inhibition can be used for the treatment of dandruff.
The present invention provides for glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes wherein the composition comprises at least 0.04% of glycine by weight of the composition. Such microbiome balancing can be used for the treatment of dandruff.
The present invention provides for glycine or a composition comprising glycine for use as a medicament. It provides for glycine or a composition comprising glycine for use as a medication for inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition. It provides for glycine or a composition comprising glycine for use as a medication for microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
The composition is suitably applied to the hair or scalp and massaged into the surface of the scalp. Generally, an amount corresponding to about 1 to 15 ml of the composition per application is applied uniformly over the area of treatment daily or at least once a week over a time interval of at least 7 (seven) days, preferably at least 28 days, more preferably at least 30 (thirty) days.
The invention will be further illustrated by the following, non-limiting Examples.
M. restricta (CBS 7877) was revitalized on modified Leeming and Notman agar (mLNA) plates from -80 °C freezer by incubation at 32 °C for 5 days. The microbe was further cultured in 20ml of liquid growth medium modified Leeming and Notman broth (mLNB) at 32 °C for 48 hrs with shaking. Then, 1ml of the first broth culture was transferred into 9 ml of fresh mLNB and incubated at 32 °C for 48 hrs with shaking and ready to use.
Malassezia. furfur (CBS 1878) was revitalized on Pityrosporum Broth (PB) agar by incubation at 32 °C for 2 days. The microbe was further cultured in 20) ml of liquid growth medium PB broth at 32 °C for 48 hrs with shaking. Then, 1ml of the first broth culture is transferred into 9ml of fresh PB and incubated at 32 °C for 48 hrs with shaking and ready to use.
S. epidermidis (ATCC_12228) was revitalized on Tryptic soy agar (TSA) by incubation at 37 °C overnight. The microbe was further cultured in 20 ml of liquid growth medium Tryptic soy broth (TSB) at 37 °C overnight and ready to use.
C. acnes (ATCC_6919) were revitalized on TSA plates by incubation at 37 °C for 5 days anaerobically. The microbe was further cultured in 20 ml of liquid growth medium TSB at 37 °C for 4 days anaerobically and ready to use.
Prepare the growth medium agar plate without glycine (control) and with different levels (weight percentage) of glycine: 0.04, 0.05, 0.1 , 0.15, and 0.2%. For the fungi M. restricta and M. furfur, mLNA was used. For the bacteria S. epidermidis and C. acnes, TSA was used.
The optical density (OD) of each microbial culture was adjusted. For M. restricta, OD = 2, 1, 0.5 and 0.25; For M. furfur, OD = 0.8, 0.4, 0.2 and 0.1 ; For S. epidermidis and C. acnes, OD = 0.6, with serial 10-fold dilutions to achieve 0.6, 0.6X10M , 0.6X10A-2, 0.6X10A-3, 0.6X10A-4, 0.6X10A-5, and 0.6X10A-6. Transfer 4pL of each microbial
inoculum onto the corresponding plates and incubate to monitor microbial growth. Duplicate experimental sets were performed. Finally, the plates with the growing colonies were visually observed at daily base up to 7 days for Malassezia and C. acnes and up to 2 days for S. epidermidis. The microbial growth at different conditions were compared by colony densities. “No inhibition” means there’s no change of microbial colony densities visually observed, “inhibition” means the growth of the microbes is inhibited with at least 75% reduced microbial colony densities, and “no growth” means almost no visible growth of microbial colony is observed.
Results
The growth of microbes was recorded and showed in Table- 1 below:
It is evident from the table above that samples 1 to 5 comprising glycine at a level consistent with the present invention were able to selectively inhibit the growth of harmful microbes (/W. restricta) while having no inhibition effect on the growth of beneficial microbes (S.epidermidis and C. acnes). Furthermore, the result in table above indicates that the using of composition comprising glycine at a level consistent with the present invention has less impact on the number of other Malassezia genus, such as Malassezia furfur (M. furfur).
Example 2
The antimicrobial efficacy of different amino acids was tested against Malassezia restricta (M. restricta). M. restricta growth was monitored with or without adding 0.5% of different amino acids by culturing M. restricta in mLNB liquid medium for 3 days. To make sure different amino acids do not impact the pH of the growth medium, the pH of
the solutions was all adjusted to the same level of pH 5.5. The same protocol was used to observe the growth of the microbes.
Results
The growth of microbes was recorded and showed in Table-2 below:
It is evident from the table above that sample 6 comprising glycine at a level consistent with the present invention were able to inhibit the growth of harmful microbes {M. restricta), while the samples comprising other amino acids cannot.
Example 3
This example demonstrated the leave-on lotions comprising glycine at certain level can inhibit the growth of Malassezia restricta {M. restricta). The compositions according to the formulations detailed in Table-3 are prepared. All ingredients are expressed by weight percent of the total formulation, and as level of active ingredient.
Table - 3
Experimental methods: Use the Agar Dilution MIC assay as Example 1 Prepare mLNA with lotion samples. Mix 10g lotion and 90g 1.1 X mLNA medium.
The optical density (OD) of M. restricta was adjusted to OD = 2, 1 , 0.5 and 0.25. 4 P L of M. restricta. suspension was added onto the agar, cultured at 32 °C for 7 days. M. restricta growth was visually observed at daily base up to 7 days. The microbial growth were compared by colony densities. “No inhibition” means there’s no change of microbial colony densities visually observed, “inhibition” means the growth of the microbes is inhibited with at least 75% reduced microbial colony densities, and “no growth” means almost no visible growth of microbial colony is observed.
Results
The growth of microbes was recorded and showed in Table-4 below:
It is evident from the table above that compositions comprising glycine at a level consistent with the present invention (Samples 7 to 9) were able to inhibit the growth of harmful microbes (M. restricta).
Claims
1. Use of glycine, or a composition comprising glycine in inhibiting the growth of Malassezia restricta when applied on an external surface of a human body; wherein the composition comprises at least 0.04% of glycine by weight of the composition.
2. Use as claimed in claim 1 wherein the composition comprising glycine in an amount of from 0.04 to 10%, preferably from 0.15 to 5%, more preferably from 0.2 to 2% by weight of the composition.
3. Use as claimed in claims 1 or 2 wherein the surface is human skin, preferably scalp.
4. Use as claimed in any of claims 1 to 3 wherein said use is for inhibiting dandruff to promote scalp health.
5. Use as claimed in any of claims 1 to 4 wherein said use has no inhibition effect on the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes.
6. Use as claimed in any of claims 1 to 5 wherein the composition is a hair or scalp composition, preferably leave-on hair or scalp composition.
7. Use of glycine or a composition comprising glycine in microbiome balancing on an externalsurface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes', wherein the composition comprises at least 0.04% of glycine by weight of the composition.
8. Use as claimed in claim 7 wherein the surface is human skin, preferably scalp.
9. Use as claimed in claims 7 or 8 wherein said use is for inhibiting dandruff to promote scalp health.
A method of applying glycine or a composition comprising glycine on an external surface of a human body for inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. A method of applying glycine or a composition comprising glycine on an external surface of a human body for microbiome balancing, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. A method of applying glycine or a composition comprising glycine on an external surface of a human body for ensuring the growth of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes while protecting the surface against harmful microbes which is Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. A method as claimed in any of claims 10 to 12 wherein the surface is human skin, preferably scalp. Glycine or a composition comprising glycine for use in microbiome balancing on an external surface of a human body, wherein balancing means selectively reducing the number of harmful microbes which is Malassezia restricta, while having no reduction effect on the number of commensal microbes selected from Staphylococcus epidermidis and Cutibacterium acnes’, wherein the composition comprises at least 0.04% of glycine by weight of the composition. Glycine or a composition comprising glycine for use in inhibiting the growth of Malassezia restricta’, wherein the composition comprises at least 0.04% of glycine by weight of the composition.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022119767 | 2022-09-20 | ||
CNPCT/CN2022/119767 | 2022-09-20 | ||
EP22203435 | 2022-10-25 | ||
EP22203435.7 | 2022-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024061608A1 true WO2024061608A1 (en) | 2024-03-28 |
Family
ID=87930093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/074228 WO2024061608A1 (en) | 2022-09-20 | 2023-09-05 | Method for inhibiting the growth of malassezia restricta |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024061608A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031188A1 (en) | 1995-04-06 | 1996-10-10 | Unilever Plc | Hair treatment compositions |
KR20090099163A (en) * | 2008-03-17 | 2009-09-22 | 장경선 | A shampoo composition comprising black mud |
US20110077193A1 (en) * | 2007-01-01 | 2011-03-31 | Bioderm Research | Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for the Treatment of Infection and Topical Condition in Mammals |
CN111643433A (en) * | 2020-07-27 | 2020-09-11 | 广州市柏亚化妆品有限公司 | Oil-control anti-dandruff shampoo composition |
WO2020244898A1 (en) * | 2019-06-06 | 2020-12-10 | Unilever N.V. | Topical composition for restoring microbial diversity of amenable skin |
-
2023
- 2023-09-05 WO PCT/EP2023/074228 patent/WO2024061608A1/en active Search and Examination
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031188A1 (en) | 1995-04-06 | 1996-10-10 | Unilever Plc | Hair treatment compositions |
US20110077193A1 (en) * | 2007-01-01 | 2011-03-31 | Bioderm Research | Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for the Treatment of Infection and Topical Condition in Mammals |
KR20090099163A (en) * | 2008-03-17 | 2009-09-22 | 장경선 | A shampoo composition comprising black mud |
WO2020244898A1 (en) * | 2019-06-06 | 2020-12-10 | Unilever N.V. | Topical composition for restoring microbial diversity of amenable skin |
CN111643433A (en) * | 2020-07-27 | 2020-09-11 | 广州市柏亚化妆品有限公司 | Oil-control anti-dandruff shampoo composition |
Non-Patent Citations (1)
Title |
---|
MURAI T. ET AL: "Differentiation of Malassezia furfur and Malassezia sympodialis by glycine utilization . Unterscheidung von Malassezia furfur und Malassezia sympodialis mittels Glycin-Verwertung", vol. 45, no. 5-6, 1 June 2002 (2002-06-01), GB, pages 180 - 183, XP093037259, ISSN: 0933-7407, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full/10.1046/j.1439-0507.2002.00757.x> [retrieved on 20230412], DOI: 10.1046/j.1439-0507.2002.00757.x * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4418976B2 (en) | Antiseptic disinfectant and cosmetic composition | |
JP7286907B2 (en) | topical composition | |
US11298312B2 (en) | Composition comprising niacinamide and picolinamide | |
JP2003081761A (en) | Emulsified composition | |
JP5039359B2 (en) | Antiseptic disinfectant and external composition for skin | |
US9943477B2 (en) | Emulsion compositions containing a novel preservative system | |
JP2007039340A (en) | Antiseptic microbicide and external composition for skin | |
WO2015123512A1 (en) | Antimicrobial Efficacy of an Oregano Oil and Caprylic Acid Blend | |
JP5264829B2 (en) | Antiseptic disinfectant and cosmetic composition | |
WO2024061608A1 (en) | Method for inhibiting the growth of malassezia restricta | |
WO2022096258A1 (en) | Use of glycerol for inhibiting growth of microbes | |
WO2024104742A1 (en) | Method for inhibiting the growth of microbes | |
CA3181110A1 (en) | An antimicrobial composition for tackling malodour | |
JP7343089B2 (en) | preservation enhancer | |
US11191772B2 (en) | Use | |
WO2021132019A1 (en) | Agent for improving cutaneous resident flora balance | |
EP3485869B1 (en) | Use of phytantriol as an antimicrobial agent in the preservation of a composition | |
JP2007001947A (en) | Cosmetic composition | |
JP2023510014A (en) | hair care composition | |
CN117941682A (en) | Antimicrobial compositions | |
KR20230074223A (en) | Novel Uses of Epilobium Plaicherry Extract | |
US20230301889A1 (en) | Method of preventing or reducing hair fall | |
EA040067B1 (en) | PROPANEDIOL MONOACETATE MONONITRATE | |
WO2010004016A1 (en) | Use of phenoxyalkylamines in cosmetic and/or dermatological compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23764942 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |